H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Carisma Therapeutics (CARM) to $5 from $8 and keeps a Buy rating on the shares post the Q3 report. The firm says the CT-0525 data was pushed to Q1 of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics reports data from its CAR-M therapy
- Carisma Therapeutics reports Q3 EPS (31c), consensus (26c)
- Carisma to present new data on CAR-M therapy for hepatocellular carcinoma
- Carisma Therapeutics, Inc. (CARM) Q3 Earnings Cheat Sheet
- Leadership Transition at Carisma Therapeutics’ Board of Directors